Vaxneuvance Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of routine pneumococcal vaccination programs, rising incidence of pneumococcal infections, increased awareness of vaccine-preventable diseases, advancements in conjugate vaccine science, improved healthcare access.

The growth in the forecast period can be attributed to increasing investments in next-generation vaccines, rising focus on elderly immunization, expansion of national immunization programs, growing demand for higher-valency vaccines, increasing adoption in emerging healthcare systems. Major trends in the forecast period include increasing adoption of broad-spectrum pneumococcal vaccines, rising focus on invasive disease prevention, growing pediatric and adult immunization coverage, expansion of conjugate vaccine technologies, enhanced emphasis on high-risk population protection.

The prevalence of pneumonia is expected to drive the growth of the Vaxneuvance market in the coming years. Pneumonia is an infection that inflames the air sacs of one or both lungs, filling them with fluid or pus, and causing symptoms such as coughing, fever, and difficulty breathing. Its prevalence is influenced by viral and bacterial infections, weakened immune systems, air pollution, and the growing aging population, which increases susceptibility to respiratory infections. Vaxneuvance protects patients against pneumonia caused by 15 strains of Streptococcus pneumoniae, reducing the risk of severe infection and associated complications. For example, according to Johns Hopkins University, a US-based research institution, the mean Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) score across 15 countries was 56% in 2024, up from 54% in 2023. Therefore, the high prevalence of pneumonia is driving the growth of the Vaxneuvance market.

The growth in research and development investments is also expected to support the expansion of the Vaxneuvance market. Investments in R&D are increasing due to the demand for innovation and the need to address complex global challenges in healthcare, sustainability, and technology. These investments support Vaxneuvance by enhancing vaccine technology and expanding its potential to meet evolving healthcare needs. For instance, according to the Office for National Statistics (ONS), a UK-based producer of official statistics, the UK government’s net R&D expenditure rose by 8.2% year-on-year, increasing from $19.9 billion in 2022 to $21.5 billion in 2023. Therefore, growing R&D investments are driving the expansion of the Vaxneuvance market.

Major companies in the Vaxneuvance (pneumococcal conjugate vaccine) market are focusing on innovative solutions, such as next-generation multivalent conjugate vaccines, to provide broader protection against pneumococcal infections. These advanced vaccines combine polysaccharides from multiple strains with a carrier protein, enhancing immune response and protection. For example, in May 2025, Vietnam Vaccine JSC (VNVC), a US-based company, introduced the 15-valent pneumococcal conjugate vaccine (PCV15 or Vaxneuvance) to expand coverage against multiple Streptococcus pneumoniae strains responsible for invasive and non-invasive diseases. The vaccine targets children from six weeks of age as well as adults, offering long-lasting immunity and helping reduce bacterial transmission within the community. This launch strengthens VNVC’s position in modern pneumococcal vaccination in Vietnam and complements its existing vaccine portfolio while supporting national immunization efforts.

Major companies operating in the vaxneuvance market are Merck & Co. Inc.

North America was the largest region in the vaxneuvance market in 2025. The regions covered in the vaxneuvance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vaxneuvance market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the vaxneuvance market by increasing costs of imported vaccine antigens, conjugation chemicals, sterile packaging components, and cold-chain distribution infrastructure. Healthcare providers and immunization programs in North America and Europe are most affected due to reliance on imported vaccine inputs, while Asia-Pacific faces higher costs in vaccine export and logistics operations. These tariffs contribute to increased vaccine procurement costs. However, they are also supporting domestic vaccine manufacturing expansion, regional supply chain development, and long-term resilience in pneumococcal vaccine production.

The vaxneuvance market research report is one of a series of new reports that provides vaxneuvance market statistics, including vaxneuvance industry global market size, regional shares, competitors with a vaxneuvance market share, detailed vaxneuvance market segments, market trends and opportunities, and any further data you may need to thrive in the vaxneuvance industry. This vaxneuvance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vaxneuvance is a pneumococcal conjugate vaccine that protects against invasive diseases caused by specific strains of Streptococcus pneumoniae in adults and children. It works by stimulating the immune system to recognize and fight 15 serotypes of the bacteria, providing broad protection.

The primary indications for Vaxneuvance are pneumonia, meningitis, sepsis, bacteremia, and otitis media. Pneumonia is an infection that inflames the air sacs in the lungs, leading to symptoms such as cough, fever, and difficulty breathing. Vaxneuvance helps prevent pneumococcal pneumonia by targeting specific serotypes of Streptococcus pneumoniae. It is distributed through pharmacies and hospitals and is used by adults, children, and elderly populations.

The vaxneuvance market consists of sales of pneumococcal 15-valent conjugate vaccines, adjuvants, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.